Download PDF

下载PDF

NEWTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) --

马萨诸塞州牛顿市，2025年11月10日（环球新闻社）--

Acumen Pharmaceuticals, Inc.

阿库门制药公司

(NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced George Golumbeski, Ph.D., has joined its Board of Directors as Chairman.

(NASDAQ: ABOS)（“Acumen”或“公司”），一家临床阶段的生物制药公司，致力于开发针对有毒可溶性β淀粉样蛋白寡聚体（AβOs）的新型疗法用于治疗阿尔茨海默病（AD），今天宣布乔治·戈卢贝斯基博士已加入公司董事会并担任主席。

Dr. Golumbeski brings more than 30 years of experience in the biopharmaceuticals industry, with extensive expertise in portfolio strategy, strategic collaborations and licensing, and M&A. The addition of Dr. Golumbeski brings the Acumen Board to eight members..

戈卢姆贝斯基博士在生物制药行业拥有超过30年的经验，在投资组合战略、战略合作与许可、以及并购方面具有深厚的专业知识。戈卢姆贝斯基博士的加入使敏锐董事会成员增至八名。

“I am very pleased to welcome Dr. Golumbeski to the Acumen Board as we continue to work to develop novel disease-modifying treatments for Alzheimer’s disease,” said Daniel O’Connell, Chief Executive Officer of Acumen Pharmaceuticals. “Dr. Golumbeski is a highly experienced biopharma leader with a strong track record in strategic initiatives and forging transformational partnerships and collaborations that have enabled the development of innovative treatment options for people with AD.

“我非常高兴欢迎戈卢姆贝斯基博士加入Acumen董事会，因为我们继续努力为阿尔茨海默病开发新型疾病修饰治疗方案，”Acumen制药公司首席执行官丹尼尔·奥康奈尔表示。“戈卢姆贝斯基博士是一位经验丰富的生物制药领导者，在战略举措和建立变革性合作伙伴关系及合作方面有着良好的记录，这些举措促进了为阿尔茨海默病患者提供创新治疗选择的进程。”

George’s deep expertise aligns with our current growth objectives as we anticipate important catalysts next year for our ongoing Phase 2 trial of sabirnetug and our Enhanced Brain Delivery program, both of which we believe can benefit people living with AD and drive value for shareholders.”.

乔治的深厚专业知识与我们当前的增长目标一致，因为我们预计明年将有重要的催化剂，用于我们正在进行的Sabirnetug二期试验和增强脑部递送计划，我们相信这两项计划都能使阿尔茨海默病患者受益并为股东创造价值。"

“Having seen first-hand the positive impact that innovation can have on the lives of people living with difficult-to-treat diseases, I could not be more excited to join the Acumen Board at this stage in the Company’s development,” said Dr. Golumbeski. “The unmet need in Alzheimer’s is massive and urgently needs impactful analysis.

“我亲眼目睹了创新可以为难以治疗的疾病患者生活带来的积极影响，因此在公司发展的这个阶段加入Acumen董事会，我感到无比兴奋，”Golumbeski博士说道。“阿尔茨海默病领域存在巨大的未满足需求，迫切需要有影响力的分析。”

The field is at an important inflection point. I look forward to collaborating with the other members of Acumen’s Board, leadership and the entire team dedicated to advancing Acumen’s programs with the goal of improving the lives of people impacted by Alzheimer’s, including people with early AD, their families and caregivers.”.

该领域正处于一个重要的转折点。我期待与Acumen董事会其他成员、领导层以及整个团队合作，共同推进Acumen的项目，目标是改善受阿尔茨海默病影响的人们的生活，包括早期阿尔茨海默病患者、他们的家人和护理人员。

Currently, Dr. Golumbeski is dedicated to helping develop young companies at DROIA Ventures, a specialist biotech investment firm. For nearly a decade, Dr. Golumbeski served as Executive Vice President of Business Development at Celgene, where he was responsible for forging collaborations with biotechnology companies seeking to bring breakthrough medicines to people suffering from cancer and chronic inflammation.

目前，戈卢姆贝斯基博士正致力于在专门从事生物技术投资的公司DROIA Ventures帮助发展年轻公司。近十年来，戈卢姆贝斯基博士担任Celgene公司业务发展的执行副总裁，负责与生物技术公司建立合作关系，力求为癌症和慢性炎症患者带来突破性药物。

Prior to joining Celgene, Dr. Golumbeski held leadership positions in business development at Novartis Pharmaceuticals and Elan Pharmaceuticals. At Elan, he worked exclusively on neurology and neurodegeneration. He holds a Ph.D. in Genetics from the University of Wisconsin-Madison, conducted his post-doctoral research in molecular biology at the University of Colorado-Boulder, and holds a B.A.

在加入新基公司之前，戈卢姆贝斯基博士曾在诺华制药和埃兰制药担任业务发展方面的领导职务。在埃兰，他专注于神经学和神经退行性疾病的研究。他拥有威斯康星大学麦迪逊分校的遗传学博士学位，在科罗拉多大学博尔德分校进行了分子生物学的博士后研究，并持有文学学士学位。

in Biology from the University of Virginia..

弗吉尼亚大学生物学博士。

About Acumen Pharmaceuticals, Inc.

关于Acumen Pharmaceuticals公司

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology.

Acumen制药是一家临床阶段的生物制药公司，正在开发一种新型疗法，靶向有毒的可溶性β淀粉样蛋白寡聚体（AβOs），用于治疗阿尔茨海默病（AD）。Acumen的科学创始人开创了针对AβOs的研究，越来越多的证据表明，这些寡聚体是阿尔茨海默病病理的早期和持续触发因素。

Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in people with early Alzheimer’s disease, following positive results in its Phase 1 trial INTERCEPT-AD.

Acumen目前正专注于在其正在进行的二期临床试验ALTITUDE-AD（NCT06335173）中推进其研究性产品候选药物sabirnetug（ACU193），这是一种选择性靶向有毒可溶性AβOs的人源化单克隆抗体，针对早期阿尔茨海默病患者。此前，该药物在一期临床试验INTERCEPT-AD中取得了积极结果。

Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology.

Acumen还在利用Halozyme的专有ENHANZE®药物递送技术研究sabirnetug的皮下制剂。Acumen还与JCR Pharmaceuticals合作，利用一种靶向转铁蛋白受体的血脑屏障穿透技术，开发用于阿尔茨海默病的增强脑部递送（EBD™）疗法。

The company is headquartered in Newton, Mass. For more information, visit .

公司总部位于马萨诸塞州牛顿。欲了解更多信息，请访问 。

www.acumenpharm.com

www.acumenpharm.com

.

。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.

本新闻稿包含《1995年私人证券诉讼改革法案》所指的前瞻性陈述。任何描述Acumen的目标、预期、财务或其他预测、意图或信念的陈述均为前瞻性陈述，应被视为有风险的陈述。

Words such as “believes,” “expects,” “anticipates,” “could,” “should,” “would,” “seeks,” “aims,” “plans,” “potential,” “will,” “milestone” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning the therapeutic potential of Acumen’s product candidate, sabirnetug (ACU193), including against other antibodies, the timing of anticipated topline results of ALTITUDE-AD, and the potential to develop a candidate to treat Alzheimer's Disease utilizing EBD technology.

诸如“相信”、“预期”、“预计”、“可能”、“应该”、“将会”、“寻求”、“目标”、“计划”、“潜力”、“将要”、“里程碑”等词语以及类似表达旨在识别前瞻性陈述，尽管并非所有前瞻性陈述都包含这些识别词。前瞻性陈述包括关于Acumen的产品候选物sabirnetug（ACU193）治疗潜力的声明，包括与其他抗体相比的潜力、ALTITUDE-AD预期顶线结果的时间安排，以及利用EBD技术研发阿尔茨海默病治疗候选药物的潜力。

These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets.

这些声明基于 Acumen 管理层当前的信念和期望，并受某些因素、风险和不确定性的影响，特别是那些在发现、开发和商业化安全有效的人类治疗药物过程中固有的风险。此类风险可能会因地缘政治事件和宏观经济状况的影响而放大，例如通货膨胀和利率上升、供应中断以及信贷和金融市场的不确定性。

These and other risks concerning Acumen’s programs are described in additional detail in Acumen’s filings with the Securities and Exchange Commission (“SEC”), including in Acumen’s most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen.

这些与 Acumen 计划相关的风险及其他风险在 Acumen 向美国证券交易委员会（“SEC”）提交的文件中有更详细的描述，包括 Acumen 最近的年度报告 Form 10-K，以及随后向 SEC 提交的文件。这些文件及其他文件的副本可从 Acumen 获取。

Additional information will be made available in o.

更多信息将在 o 中提供。

CONTACTS:

联系人：

Investors:

投资者：

Alex Braun

亚历克斯·布劳恩

abraun@acumenpharm.com

abraun@acumenpharm.com

Media:

媒体：

AcumenPR@icrhealthcare.com

AcumenPR@icrhealthcare.com